Related Experiment Video

Updated: Jun 29, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

The management of viral hepatitis in CKD patients: an unresolved problem

C Molino1, F Fabbian, M Cozzolino

  • 1Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy. clinicamedica@unife.it

The International Journal of Artificial Organs
|October 1, 2008
PubMed

Insights

Chronic kidney disease patients on dialysis face unique health challenges, including viral hepatitis. Strict infection control has reduced hepatitis B virus (HBV) and hepatitis C virus (HCV) in dialysis, but they remain significant risk factors for mortality.

Area of Science:

  • Nephrology
  • Hepatology
  • Infectious Diseases

Background:

  • Patients undergoing hemodialysis (HD) for chronic kidney disease (CKD) exhibit distinct clinical presentations and disease patterns.
  • CKD patients are a high-risk group for viral hepatitis, with hepatitis B virus (HBV) historically being a major concern in end-stage renal disease (ESRD).
  • Implementation of rigorous infection control strategies has significantly decreased HBV transmission in dialysis settings.

Purpose of the Study:

  • To review the epidemiology and clinical implications of viral hepatitis, specifically HBV and HCV, in patients with CKD undergoing dialysis.
  • To assess the impact of infection control measures on HBV and HCV prevalence in dialysis patients.
  • To highlight the independent and significant risk of HBV and HCV for mortality in CKD patients.

Main Methods:

  • Review of existing literature and epidemiological data on viral hepatitis in CKD and dialysis patients.
  • Analysis of the impact of infection control strategies, screening, vaccination, and erythropoietin use on HBV and HCV prevalence.
  • Examination of the relationship between viral hepatitis and mortality risk in this patient population.

Main Results:

  • Strict infection control, including screening, vaccination, and isolation protocols, has led to a marked decline in HBV prevalence among dialysis patients.
  • Hepatitis C virus (HCV) prevalence has also decreased, ranging from 5% to 25% in the US and 6.8% in Europe, following routine screening and erythropoietin use.
  • Both HBV and HCV are independent and significant risk factors for mortality in CKD and HD patients, partly due to associated chronic liver disease and complications.

Conclusions:

  • While infection control has improved, viral hepatitis remains a critical concern for CKD patients on dialysis.
  • The immune dysfunction inherent in kidney disease influences the natural history of viral hepatitis in these patients.
  • Further research is needed to clarify the efficacy and long-term outcomes of antiviral therapies in this vulnerable population.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...